Can medications like Ozempic, Wegovy, and Zepbound change how much you want to drink alcohol? Emerging research suggests they may. GLP-1 medications, particularly semaglutide, may influence the brain's reward system, reduce alcohol cravings, and help some people reduce heavy drinking.
In this episode, I explain how GLP-1 medications work and why they may affect more than appetite. I also break down recent clinical trials examining semaglutide and alcohol consumption, including what researchers have discovered about cravings, heavy drinking, and the difference between drinking less and stopping altogether.
Episode Highlights:
-
How GLP-1 medications may influence the brain's reward system and alcohol cravings.
-
What dopamine has to do with drinking habits and the concept of alcohol noise.
-
What recent clinical trials reveal about semaglutide and heavy drinking.
-
Why reduced alcohol cravings don't necessarily mean someone will stop drinking.
-
What to consider if you're drinking alcohol while taking GLP-1 medication.
-
Why GLP-1 medications are not yet FDA-approved to treat alcohol use disorder.
-
What researchers are discovering about GLP-1 medications and other addictive behaviors.
The research is promising, but there is still much we need to understand. GLP-1 medications may help some people reduce heavy drinking, but they are not a replacement for established alcohol use disorder treatments.
And remember, alcohol use disorder is a medical condition, not a failure of willpower. Asking for help is a sign of taking your health seriously.
If you found this episode helpful, share it with someone who might benefit from this information. Leave a comment, like, and subscribe for more conversations about achieving healthy weight loss and improving your health.
Research References-
Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395–405. doi:10.1001/jamapsychiatry.2024.4789
-
Klausen MK, Justesen SK, Pedersen JN, Rasmussen L, Jensen A, Jensen ME, Knorr UB, Bergmann ML, Holst JJ, Hartmann B, Koob GF, Benveniste H, Volkow ND, Ekstrøm CT, Knudsen GM, Vilsbøll T, Fink-Jensen A. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. The Lancet. 2026 May 2;407(10540):1687–1698. doi:10.1016/S0140-6736(26)00305-3.
-
Schacht JP, Sakai JT, Raymond K, Shelton R. Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial. American Journal of Psychiatry. 2026;183(9):636–645. doi:10.1176/appi.ajp.20260003.
Connect with Dr. Alicia Shelly
-
Website | drshellymd.com
-
Facebook | www.facebook.com/drshellymd
-
Instagram | @drshellymd
-
Linked In | www.linkedin.com/in/drshellymd
-
Twitter | @drshellymd
About Dr. Alicia Shelly
Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH. Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014. In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss, where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.
Resources:
FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!) 👉 Click HERE
[00:00:00] Welcome back to the Back on Track: Achieving Healthy Weight Loss, where I help you get on track and stay on track with your weight loss journey. I'm your host, Dr. Alicia Shelly. So let's get started.
[00:00:27] Welcome back to the Back on Track Achieving Healthy Weight Loss podcast. I'm your host, Dr. Alicia Shelly. And today we're going to be talking about something that's been getting a lot of attention.
[00:00:38] Can medications like Ozempic, Wagovi and Zeppound actually change your desire to drink alcohol? Maybe you heard of someone say, ever since I started my GLP-1 medication, I just don't want wine anymore. Or perhaps you've experienced this yourself. You used to enjoy a glass of wine with dinner or a cocktail on the weekend, but now you take a few sips and you just simply lose interest.
[00:01:04] What is actually going on? Is this just because medications make you feel full? Or could they actually be changing how your body responds to alcohol? And could these medications someday become a treatment for alcohol addiction? Well, the research is becoming more interesting. In fact, several clinical trials, including studies published in 2025 and 2026, have found that semaglutide may help people reduce heavy drinking.
[00:01:34] But there is an important difference between drinking less and stopping drinking altogether. And there is also a difference between what we know about semaglutide and what we know about other medications like trizepatide. And today, we're just going to break it all down, what the science tells us, what researchers are discovering, and what this could mean for your health. So first, let's review how these medications work.
[00:01:59] GLP-1 stands for glucagon-like peptide, number one. And it is the hormone that your body naturally makes, especially after you eat. GLP-1 is also made in certain parts of the brain. GLP-1 helps control blood sugar, slows how quickly food leaves your stomach, and sends signals to your brain to help you feel full. Medications like semaglutide, found in Ozempic and Wagovi, copy the effects of this hormone.
[00:02:27] Guseppatide, found in Mounjaro and Zepbound, works on two hormone pathways, GLP-1 and GIP. These medications help many people eat less, feel satisfied sooner, and lose weight. The here is where things get interesting. Scientists have learned that GLP-1s also affect areas of the brain involved in motivation, cravings, and rewards. And these brain systems do not just respond to food. They also respond to alcohol.
[00:02:57] Now, I want to make one important point early in our discussion. Most of the stronger clinical trial evidence about alcohol use involves semaglutide. Although researchers are also studying tirzepatide, we do not yet have the same level of clinical trial evidence showing that tirzepatide reduces alcohol use in humans. And so we should not assume that every GLP-1 medication has the same effect.
[00:03:23] So the majority of our podcasts, when I discuss the different studies, we'll be looking at semaglutide. But first, let's understand the connection. What does alcohol have to do with the brain's reward system? And to understand that, we need to talk about dopamine. Dopamine is a chemical messenger in your brain. It helps you learn what feels rewarding and what you may want to do again.
[00:03:49] When you eat your favorite food or drink alcohol, your brain's reward system becomes active. Over time, your brain can learn to connect certain experiences with a reward. For example, maybe every Friday evening you have a glass of wine to relax. Eventually, just getting home on Friday may trigger the desire for wine. That is because your brain has learned to connect that experience with the reward, which is wine.
[00:04:15] Now, GLP-1 medications appear to influence some of these same brain pathways. Researchers believe that these medications may reduce how strongly the brain responds to certain rewards, including alcohol. This does not mean they turn off dopamine or remove your ability to enjoy life. Absolutely not. Instead, they may make certain cravings feel less powerful. Some people describe this as having less food noise.
[00:04:41] And a food noise refers to those constant thoughts about food, what to eat next, when can you eat again. Researchers are now studying whether something similar happens with alcohol. Could GLP-1 medications reduce what we might call as alcohol noise? Think about someone who used to spend Friday afternoon looking forward to having a drink afterward. And after starting semaglutide, that same person may realize that they haven't thought about drinking at all.
[00:05:10] And for some people, early research suggests that this may happen. But the big question is whether these changes actually lead to drinking less. And that brings us to the research. For years, researchers have studied GLP-1 medications in animals. They found that certain GLP-1 medications could reduce alcohol intake in mice, rats, and even in some non-human primates. But animal studies do not always predict what happens in people.
[00:05:39] So scientists begin conducting human studies. And now we have several important trials. So the first trial is the 2025 JAMA Psychiatry Study. One important study published in 2025 in JAMA Psychiatry looked at semaglutide in adults with alcohol use disorder. Alcohol use disorder is a medical condition in which a person who has trouble controlling their alcohol use, even when drinking, is causing problems. And here is something important about this study.
[00:06:09] The participants all had alcohol use disorder, but they were not actively seeking treatment to stop drinking. The researchers divided 48 participants in two groups. One group received semaglutide. The other received a placebo. A placebo looks like the medication that does not contain the active drug. The researchers gradually increased the semaglutide dose starting at 0.25 milligrams, then increasing to 0.5 milligrams with a target of 1 milligrams.
[00:06:39] And the study lasted nine weeks. And here's what they found. During a controlled drinking test, participants taking semaglutide drank less alcohol than those taking the placebo. They also had lower peak breath alcohol levels. In other words, when alcohol was available, the people taking semaglutide tended to drink less. Researchers also looked at what happened in everyday life. People taking semaglutide reported fewer drinks on days that they did drink.
[00:07:09] And they also reported less alcohol cravings and showed improvements in heavy drinking over time. But here's an important detail. The number of days they drank did not significantly decrease compared with the placebo group. The average number of drinks per calendar day did not significantly change as well. So what does that mean? They were not necessarily drinking on fewer days, but when they did drink, they tended to drink less.
[00:07:37] And that is an important difference. The researchers also noticed that some of the benefits became stronger as the semaglutide dose increased. However, this was a very, very small study with only 48 participants divided between two groups. So researchers needed a larger and longer study. And let us look to May 2026.
[00:07:59] A study published in the Lancet called the Simalco S-E-M-A-L-C-O trial provided more evidence. This study included 108 people, so double, who had both obesity and alcohol use disorder. Unlike the earlier study, these participants were seeking treatment for their alcohol use. In fact, about 85% had severe alcohol use disorder. Researchers divided participants into two groups.
[00:08:28] One group received semaglutide with a target dose of 2.4 milligrams, and the other group received a placebo. Both groups also received cognitive behavioral therapy. And that is the type of counseling that helps people recognize and change patterns of thinking and behavior. The study lasted 26 weeks or about six months, so even longer than what the first trial looked at. And the results were encouraging. In the semaglutide group, heavy drinking days decreased by about 41%.
[00:08:57] And in the placebo group, heavy drinking days decreased by about 26 percentage points. That means semaglutide group had a greater reduction in heavy drinking days. Researchers also found improvement in the total amount of alcohol consumed and the number of drinks on the drinking days and alcohol cravings. This is important because the study followed people for a longer period and included participants who were actively seeking help.
[00:09:24] But we also need to remember that both groups also received counseling. And even though semaglutide appeared to provide an added benefit, this study does not tell us whether the same results would happen without the counseling. The last trial I want to share with you is the 2026 oral semaglutide study. This looked at oral semaglutide or the Wagovi pill or the pill form of the semaglutide.
[00:09:49] Researchers found that participants taking oral semaglutide had fewer heavy drinking days and fewer drinks on the days they did drink. They also reported less cravings in everyday life and fewer problems related to alcohol use. However, not every measure improved. For example, the number of drinking days did not significantly decrease and cravings measured in laboratory did not show any significant improvement.
[00:10:13] So once again, the pattern was similar as before, but people taking semaglutide appeared to reduce how much they drank, especially heavy drinking. But that did not necessarily mean that they stopped drinking altogether. Now, the another important point is that not every GLP-1 medication has shown the same results. An earlier study looked at exanatide or Bidurion or Bayetta, another medication that works on the GOP-1 pathway.
[00:10:42] That study did not meet its main goal of reducing heavy drinking across the entire study group. However, researchers did see possible benefits among participants with obesity. This tells us that the response may depend on the medication and the person taking it. We also have observational studies suggesting that people taking medications like semaglutide may have fewer alcohol-related health problems. Hmm.
[00:11:09] Some studies have found lower rates of alcohol use disorder diagnosis or hospitalizations. But observational studies cannot prove that the medication caused these improvements. And although early research involving trisapatite is encouraging, we still need randomized clinical trials specifically testing trisapatite for alcohol use disorder. So what is the bottom line? We know.
[00:11:36] We now have several randomized clinical trials, including a six-month study suggesting that semaglutide may reduce heavy drinking. And that is encouraging. But these studies are still fairly modest in size. 48 participants, 108 participants, who do not know whether the benefit continues after someone stops taking the medication as well. So how does GLP-1 medications reduce alcohol cravings? And there are several reasons.
[00:12:04] First, the brain reward system may change. Alcohol may simply feel less appealing or less rewarding for some people taking these medications. Secondly, cravings may decrease. Someone who previously looked forward to drinking may notice that they're not thinking about alcohol as often. Remember our discussion about food noise? For some people, alcohol noise may also become quieter. And then thirdly, the medications can change how people feel physically.
[00:12:32] GOP-1 medications slow stomach emptying and may cause nausea or fullness. As a result, drinking alcohol may become less comfortable or enjoyable. And in fact, in the 2026 SimAlco study, nausea was reported by 57% of participants taking semaglutide compared with 7% taking the placebo. That is a pretty big difference. And it's an important question. Are people drinking less because their brain is less interested in alcohol?
[00:13:01] Or are they drinking less because they feel nauseated or full? The answer may be a combination of both. Researchers are still trying to understand exactly how these medications affect alcohol use. And remember, not everyone taking a GOP-1 medication notices a change in their desire to drink. This is one of the biggest questions researchers are trying to answer. Alcohol use disorder affects millions of people and can lead to serious health problems.
[00:13:29] These can include liver disease, heart disease, certain cancers, and injuries. We already have three FDA-approved medications that can help treat alcohol use disorder. These include naltrexone, acomprosate, and disulfiram. And they work in different ways. Naltrexone can help reduce the rewarding effects of alcohol and decrease heavy drinking. Acomprosate can help people maintain abstinence, which means not drinking alcohol.
[00:13:59] And disulfiram causes an unpleasant reaction when somebody drinks alcohol, which helps certain patients avoid drinking altogether. These medications can be helpful when combined with counseling and other support. So where do GOP-1 medications fit in? Right now, they're still being studied. And I want to emphasize something. Reducing heavy drinking is not the same as treating alcohol use disorder successfully for every person.
[00:14:25] The semaglutide studies have shown improvement in heavy drinking and the amount of alcohol consumed. But they have not consistently shown that people stop drinking completely or even drink on fewer days. That does not mean reducing heavy drinking is unimportant. Drinking less can have meaningful health benefits. But we still need to understand whether these medications can help people achieve and maintain their personal treatment goals over time.
[00:14:53] We also need to answer several questions, which is, what happens when somebody stops taking the medications? Will the alcohol cravings return? Do these medications work equally well in people with mild, moderate, or severe alcohol use disorder? And which patients are most likely to benefit? We simply do not have all the answers yet. And for now, no GOP-1 medication is FDA approved to treat alcohol use disorder.
[00:15:21] And these medications should not replace proven treatments. And one more important part. If someone drinks heavily every day, they should not suddenly stop drinking without medical guidance. Alcohol withdrawal can be dangerous and sometimes even life-threatening. And there are safe and effective ways to get help. So please follow up with your healthcare provider if you fall in that category. So what if you are taking a GOP-1 and still drinking alcohol? What happens?
[00:15:50] That is a very practical question. There is not a universal rule that everyone taking these medications must avoid alcohol. However, there are several important things to consider. First, nausea and stomach discomfort. Both alcohol and GOP-1 medications can contribute to nausea, vomiting, and stomach discomfort. So if you already experience these side effects, alcohol may make them worse. Secondly, alcohol contains calories.
[00:16:18] Alcohol can add calories without even providing much nutrition. So if you are working towards weight loss, reducing alcohol may help you meet your goals. Thirdly, alcohol can affect your blood sugar. This is especially important for people with diabetes who take insulin or medications because alcohol can increase the risk of low blood sugar, especially if you have not eaten enough. And then fourth, dehydration. Alcohol can contribute to dehydration.
[00:16:45] If you're already dealing with nausea, vomiting, or diarrhea from your medication, dehydration can become a bigger concern. Fifth, we have to consider your overall health. Alcohol can affect your sleep, judgment, and food choices. And for some people, drinking alcohol may carry additional risks because of other medical conditions. My advice is to pay attention to how your body responds.
[00:17:10] If you notice that alcohol no longer appeals to you, you do not need to force yourself to drink. And if you choose to drink, discuss your individual risks with your healthcare professional, especially if you have diabetes, liver disease, or a history of pancreatitis, or concerns about alcohol use. So could GOP-1 medications change other cravings? This is another area of growing research.
[00:17:36] Scientists are studying whether GOP-1 medications may affect cravings related to nicotine or other substances. The reason is that several addictive substances involve overlapping brain rewards pathways. But we need to be careful. Just because a medication affects cravings for food or alcohol does not mean it will automatically treat every addiction. For example, a 2026 study looked at semaglutide in people who smoked cigarettes daily.
[00:18:03] Researchers found that semaglutide reduced cigarette cravings, but it did not significantly reduce the number of cigarettes people smoke every day. That is a great example of why we have to look beyond cravings. Feeling less interested in something does not always mean a person's behavior will change. And different substances affect the brain in different ways. So while this research is exciting, we still need strong clinical trials before recommending these medications for other addictions.
[00:18:32] And so here are my four things I want you to remember from today's episode. Number one, GOP-1 medications may affect more than appetite. They appear to influence brain pathways involved in cravings and rewards. It may help explain why some people notice less interest in alcohol. Number two, we now have several clinical trials showing promising results.
[00:18:56] Studies published in 2025, 2026 suggest that semaglutide may help reduce heavy drinking, alcohol cravings, and the amount people drink. This is no longer based on one small study. But the evidence is still developing. Number three, drinking less is not the same as stopping drinking. In several studies, people taking semaglutide drank less when they did drink. But the number of days they drank did not always change. And that distinction matters.
[00:19:26] Number four, GOP-1 medications are not currently approved to treat alcohol use disorder. We already have effective treatments, including medications and counseling. But if you or someone you know is struggling with alcohol use, there is help available. An alcohol use disorder is in medical condition and is not a failure of willpower. Asking for help is a sign of taking your health seriously.
[00:19:49] I think one of the most exciting things about obesity medicine is that we are learning more about how closely our gut, hormones, and brain are connected. And for years, we focused on how GOP-1 medications affect hunger, blood sugar, and weight. But now researchers are exploring how these medications may influence other behaviors, including alcohol use. And the research is becoming much more promising. We now have several clinical trials suggesting that semaglutide may help people reduce heavy drinking.
[00:20:19] But there are still important questions about long-term outcomes and which patients benefit most and what happens when the medication is stopped. So for now, the message is GOP-1 medications may change your desire for alcohol. For some people, they may need fewer cravings or less drinking. But they're not yet a proven replacement for established alcohol use treatment. Thank you again for joining me on another episode of the Back on Track Achieving Healthy Weight Loss podcast.
[00:20:47] If you found today's episode helpful, share it with a friend who might benefit from this information. And I would love to hear from you. So leave a comment as well as don't forget to like and subscribe. And until next time, stay strong, stay committed, and stay consistent. And remember, we are stronger together.
